Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/1671
Title: OC-0277 Interim safety analysis of RAPPORT trial - SABR with pembrolizumab in oligometastatic RCC.
Authors: Moon, Daniel
Sandhu, Suneet
Tran, Ben
Goad, Jeremy
Lawrentschuk, Nathan
Murphy, Declan
Other Authors: Siva, Shankar
Bressel, Mathias
Mooi, Jennifer
Lewin, Jeremy
Loi, Sherene
Toner, Guy
Shaw, Mark
Chander, Sarat
Eade, Thomas
Keywords: SABR
Stereotactic Ablative Radiotherapy
RCC
Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Metastases
RAPPORT Clinical Trial
Disease Control
Radiotherapy
Interim Safety Analysis
Pembrolizumab
CTCAE
Common Terminology Criteria for Adverse Events
Epworth Prostate Centre, Epworth HealthCare Richmond, Melbourne, Australia
Epworth HealthCare
Issue Date: Apr-2019
Publisher: Elsevier
Citation: (2019). OC-0277 Interim safety analysis of RAPPORT trial-SABR with pembrolizumab in oligometastatic RCC. Radiotherapy and Oncology, 133, S137.
Abstract: SABR is a locally effective modality for metastatic renal cell carcinoma (RCC) (1, 2). Preclinical data in RCC has demonstrated improved disease control in both irradiated and unirradiated sites with single fraction SABR and anti-PD1 checkpoint blockade (3), although prospective clinical trials with this combination have not yet been reported. RAPPORT is a multi-institutional, single arm, phase 1b/II clinical trial (NCT02855203). Patients with 1-5 oligometastases from clear cell RCC were eligible. They received a single fraction SABR of 18-20Gy to all metastases (or 30Gy in 10 fractions of conventional radiotherapy if SABR was not feasible) followed by 8 x 3 weekly cycles of 200mg intravenous pembrolizumab. This is a preplanned interim safety analysis of the first 12 patients who completed SABR and 12 weeks of pembrolizumab. Adverse events were graded using CTCAE v4.0.
URI: http://hdl.handle.net/11434/1671
DOI: 10.1016/S0167-8140(19)30697-8
PubMed URL: https://www.thegreenjournal.com/article/S0167-8140(19)30697-8/abstract
Journal Title: Radiotherapy & Oncology
Type: Journal Article
Affiliated Organisations: Peter MacCallum Cancer Centre, Melbourne, Australia
Peter MacCallum Cancer Centre, Biostatistics and Clinical Trials, Melbourne, Australia
Northern Sydney Cancer Centre, Oncology, Sydney, Australia
Princess Alexandra Hospital, Oncology, Brisbane, Australia
Type of Clinical Study or Trial: Clinical Trial
Appears in Collections:Radiation Oncology
Research Week
UroRenal, Vascular

Files in This Item:
File Description SizeFormat 
OC-0277InterimSafetyAnalysisOfRAPPORTTrial_April2019.pdf176.45 kBAdobe PDFThumbnail
View/Open


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.